JAJessica Alber

Jessica Alber

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jessica Alber has a total of 189 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Update on the current state of speech and language testing in Alzheimer's disease

    by Shloka Dhareshwar, Melissa Kane, Courtney Lewis, Ruby Mineur, Kylie Yao, Peter J. Snyder, Jessica Alber, Catherine Robb, Yen Ying Lim, Adam P. Vogel

    Alzheimer's disease (AD) causes alterations in speech and language across multiple domains, including semantic content, pragmatics, prosody, morphosyntax, phonology and timing/fluency, with some of these changes detectable early in the disease course. Definitive biomarker assessments of AD are often invasive or resource-intensive; there is a need for scalable measures in screening and monitoring AD. Advances in natural language processing and automated transcription can quantify speech and language features from structured tasks and natural conversations. This review summarizes domain-specific changes across the AD continuum, evaluates evidence linking these features to biomarkers of AD pathology (amyloid and tau), and discusses opportunities and limitations for future work. We conclude by identifying priorities for the field, namely, domain-aware task design, demographic and language-sensitive norms and standardized, biomarker-validated datasets.


  • Open Access

    The Relationship Between Gait Task Performance and Plasma Biomarkers for Alzheimer’s Disease in Cognitively Unimpaired Older Adults and Patients with Mild Cognitive Impairment

    by Jordan Sergio, Ashley Price, Peter Snyder, Savannah Doster, Maeve Durkin, Jennifer Strenger, Louisa Thompson, Megan Stradtman, Stuart Sinoff, Jessica Alber

    The Timed Up and Go (TUG) is a 20-foot gait assessment, with TUG-dual task (DT) serial subtractions to determine dual-task cost. Alzheimer’s disease (AD) risk is established using plasma biomarkers and APOE genotyping. We investigated: 1) TUG/TUG-DT differences between AD low-risk cognitively unimpaired (CU) older adults (N = 74), AD high-risk CU older adults (N = 87), and mild cognitively impaired (MCI) older adults (N = 33) and 2) the relationship between TUG/TUG-DT performance and plasma biomarkers. One hundred and ninety-four older adults ages 55–80 completed TUG/TUG-DT, a fasting blood draw, and APOE genotyping. Scores on the Clinical Dementia Rating Scale (CU = 0; CI = ≥0.5) and Montreal Cognitive Assessment (CU ≥ 24; CI = ≤23) determined whether participants were placed into the CU low-risk, CU high-risk, or MCI groups. Risk level for CU participants were assessed by APOE genotyping. Those participants who carried at least one copy of the APOE ε4 allele were designated to the high-risk group (n = 87). Participants with no APOE ε4 allele were assigned to the low-risk group (n = 75). MCI participants took longer to perform the TUG than CU participants (p < 0.001). CU high-risk and MCI group performed similarly on step counts, while the CU low-risk took significantly fewer steps (p<0.001). Speed predicted whether someone was below an AD-risk threshold for pTau217 in CU participants (n = 150). Exploratory generalized additive models showed plasma biomarkers predicted gait metrics in CU groups. Step count may be more sensitive, compared to speed alone, in identifying those in preclinical AD stages. Gait metrics (speed and efficiency) played a key role as a clinical manifestation of early AD pathophysiology determined by blood-based biomarker concentration. Combining these assessments offers a multidimensional, cost-effective approach for preclinical-AD screening and potential early intervention.


  • Open Access

    Pilot study examining the relationship between retinal vasculature and cognition in older adults recently discharged from a 12-week cardiac rehabilitation program

    by Jordan Sergio, Emma Gosselin, Edmund Arthur, Wen-Chih Wu, Jessica Alber

    Background: Cardiovascular disease increases the risk for cerebrovascular disease (CBVD) and cognitive decline. The retina has become an ideal target for imaging cerebrovascular changes via optical coherence tomography angiography (OCTA). Whether OCTA metrics map onto clinical outcomes in adults at high risk for CBVD and cognitive decline remains unknown. Objectives: This study examined the relationship between OCTA metrics and domain-specific cognition in older adults recently discharged from a 12-week cardiac rehabilitation program, who are at high risk of both CBVD and cognitive decline. Design: This was a prospective, feasibility/pilot study to determine whether OCTA metrics are related to cognition in this unique population of high-risk adults. Methods: Twenty-two older adults recruited within 3 months of completing a 12-week cardiac rehabilitation program participated in a single visit consisting of cognitive assessment and OCTA imaging. Cardiac/exercise metrics were compared pre- and post-rehabilitation. Primary outcomes were analyzed using partial correlation, and multiple regression assessed whether exercise moderates the relationship between retinal vasculature and cognition. Results: Higher performance in episodic memory predicted retinal vascular perfusion. Change in time spent performing exercise and change in systolic blood pressure from pre- to post-cardiac rehabilitation were associated with higher logical memory performance post-rehab. Exercise did not moderate the relationship between retinal vascular perfusion and cognition. Conclusion: The results of this study support a direct relationship between retinal vascular integrity and cognition in those at high risk for cognitive impairment and cardiovascular disease (CVD). Future research in larger samples with data collection both pre- and post-cardiac rehabilitation will inform whether this relationship is mediated by exercise.

  • Open Access

    The Predictive Value of Structural OCT in Preclinical AD

    by Jessica Alber

    Background: Research shows that structural retinal changes, measured via spectral‐domain optical coherence tomography (SD‐OCT), are sensitive diagnostic biomarkers in AD. Our recent work aims to validate retinal biomarkers as risk biomarkers in preclinical AD. We compared retinal layer thickness to plasma ptau217 (a valid measure of Aβ pathophysiology in preclinical AD) to determine the predictive value of structural retinal changes in preclinical AD.Method: A total of 120 cognitively unimpaired (CU; CDR=0, MoCA>26) older adults aged 55‐80 underwent SD‐OCT imaging. Plasma samples were analyzed with the Simoa ALZpath pTau 217 assay. Multinomial logistic regression models, with age, APOE E4 status and first degree family history as covariates, were used to assess the predictive value of each retinal layer on plasma ptau217 concentrations, with emphasis on layers that have shown thinning in clinical AD (macular retinal nerve fiber layer, mRNFL; ganglion cell layer, GCL; inner plexiform layer, IPL). Additional iterative models added mRNFL, then GCL and IPL, to assess the combined predictive value of the retinal layers. ROC analysis with assay‐specific plasma ptau217 cut‐off .495 was used to determine how well each retinal layer and/or the retinal layers combined predicted preclinical AD status. Partial correlations (controlling for age) were performed to determine the relationships between individual retinal layer thicknesses and plasma ptau217.Result: There were significant positive correlations between the thickness of the inner inferior and superior GCL and IPL and plasma ptau217 (all p<.05). Inner inferior and superior mRNFL and GCL thickness were significant predictors of plasma ptau217. The model that had the best performance included age, APOE status, first degree family history, and the inner inferior and superior thickness of the mRNFL, GCL, and IPL, with AUC = .90, (95%CI = .86‐.93, p<.01).Conclusion: Retinal thickness, measured by SD‐OCT, could be a useful screening tool to identify those at high risk for preclinical AD who may benefit from more invasive or expensive neuroimaging for confirmation. Longitudinal follow‐up is ongoing to determine the prognostic value of SD‐OCT in predicting conversion to symptomatic AD.

  • Open Access

    The bidirectional relationship between subjective visual function and domain-specific cognition in cognitively unimpaired older adults and adults with mild cognitive impairment

    by Abigail Dubois, Jordan Sergio, Sima Mozdbar, Ashley Price, Megan Stradtman, Louisa I. Thompson, Peter J. Snyder, Jessica Alber

    Introduction: Subjective visual impairment (VI) is related to cognition in cognitively unimpaired (CU) older adults, mild cognitive impairment (MCI) patients, and Alzheimer’s disease (AD) patients. The utility of subjective VI as an indicator for domain-specific cognitive impairment is unknown.Methods: We used the National Eye Institute Visual Function Questionnaire (NEI-VFQ-25 item) and a neuropsychological battery to assess the relationship between subjective VI and domain-specific cognitive performance in CU older adults (N = 58) and MCI patients (N = 16).Results: The CU group showed a positive relationship between subjective VI and visuospatial performance. CU older adults at high risk for AD demonstrated a unique relationship between subjective VI and attention, processing speed, and executive function. Peripheral vision was related to domain-specific performance in the patient group.Discussion: Subjective VI complaints may indicate potential for domain-specific cognitive decline in visuospatial performance, executive function, processing speed, and attention in older adults.


  • Added value of inflammatory plasma biomarkers to pathologic biomarkers in predicting preclinical Alzheimer's disease

    by Haley Leclerc, Athene Kw Lee, Zachary J Kunicki, Jessica Alber

    Background: Plasma biomarkers have recently emerged for the diagnosis, assessment, and disease monitoring of Alzheimer's disease (AD), but have yet to be fully validated in preclinical AD. In addition to AD pathologic plasma biomarkers (amyloid-β (Aβ) and phosphorylated tau (p-tau) species), a proteomic panel can discriminate between symptomatic AD and cognitively unimpaired older adults in a dementia clinic population. Objective: Examine the added value of a plasma proteomic panel, validated in symptomatic AD, over standard AD pathologic plasma biomarkers and demographic and genetic (apolipoprotein ( APOE) ɛ4 status) risk factors in detecting preclinical AD. Methods: 125 cognitively unimpaired older adults (mean age = 66 years) who completed Aβ PET and plasma draw were analyzed using multiple regression with Aβ PET status (positive versus negative) as the outcome to determine the best fit for predicting preclinical AD. Model 1 included age, education, and gender. Model 2 and 3 added predictors APOE ɛ4 status (carrier versus non-carrier) and AD pathologic blood biomarkers (Aβ 42/40 ratio, p-tau181), respectively. Random forest modeling established the 5 proteomic markers from the proteomic panel that best predicted Aβ PET status, and these markers were added in Model 4. Results: The best model for predicting Aβ PET status included age, years of education, APOE ɛ4 status, Aβ 42/40 ratio, and p-tau181. Adding the top 5 proteomic markers did not significantly improve the model. Conclusions: Proteomic markers in plasma did not add predictive value to standard AD pathologic plasma biomarkers in predicting preclinical AD in this sample.


  • APOE Genotype Disclosure Influences Decisions About Future Planning but not Adoption of Healthy Lifestyle Changes in Cognitively Unimpaired Individuals

    by Dominique L. Popescu, Athene K. Lee, Edmund Arthur, Louisa I. Thompson, Jessica Alber

    Background: Studies have shown apolipoprotein E (APOE) genotype disclosure to be safe and well-tolerated in cognitively unimpaired (CU) older adults. This study aimed to examine the effect of the disclosure process on decisions about future directives and health behaviors in community-dwelling CU older adults from the Butler Alzheimer’s Prevention Registry (BAPR). Methods: CU APOE E4 non-carriers (n = 106) and carriers (n = 80) aged 58-78 completed in-person psychological readiness screening to undergo APOE disclosure. Follow-up assessments were completed online 3 days, 6 weeks, and 6 months post-disclosure. The primary outcomes were future directives, dietary habits, and physical activity scores. Results: Disclosure was associated with decision making on future directives in E4 carriers ( t = 3.59, P = .01) at 6 months compared to baseline, but not non-carriers. Family history of memory impairment, SCD endorsement, and education consistently predicted scores on future directives. A significant interaction between E4+ and SCD endorsement on future directive scores was noted (OR = 163.06, 9.5-2,799.8). E4 + carrier status was associated with physical activity ( W = 60,148, P = .005) but not dietary habits scores. Conclusions: Our findings indicate that disclosure led to a change in future directives but not protective health behaviors, specifically in E4 carriers. Future work will explore whether pairing disclosure with education about the role of lifestyle factors in AD risk and providing guidelines on making risk-lowering lifestyle modifications as an intervention approach leads to positive change.


  • Open Access

    Retina pathology as a target for biomarkers for Alzheimer's disease: Current status, ophthalmopathological background, challenges, and future directions

    by Jessica Alber, Femke Bouwman, Jurre Den Haan, Robert A. Rissman, Lies De Groef, Maya Koronyo‐Hamaoui, Imre Lengyel, Dietmar Rudolf Thal, the Alzheimer's Association ISTAART “The Eye as a Biomarker for AD” Professional Interest Area

    There is emerging evidence that amyloid beta protein (Aβ) and tau‐related lesions in the retina are associated with Alzheimer's disease (AD). Aβ and hyperphosphorylated (p)‐tau deposits have been described in the retina and were associated with small amyloid spots visualized by in vivo imaging techniques as well as degeneration of the retina. These changes correlate with brain amyloid deposition as determined by histological quantification, positron emission tomography (PET) or clinical diagnosis of AD. However, the literature is not coherent on these histopathological and in vivo imaging findings. One important reason for this is the variability in the methods and the interpretation of findings across different studies. In this perspective, we indicate the critical methodological deviations among different groups and suggest a roadmap moving forward on how to harmonize (i) histopathologic examination of retinal tissue; (ii) in vivo imaging among different methods, devices, and interpretation algorithms; and (iii) inclusion/exclusion criteria for studies aiming at retinal biomarker validation.


  • Using the Montreal cognitive assessment to identify individuals with subtle cognitive decline.

    by Tess E. K. Cersonsky, Shanti Mechery, Matthew M. Carper, Louisa Thompson, Athene Lee, Jessica Alber, Indra Neil Sarkar, Leslie Ann D. Brick

    Dementia is a devastating neurological disease that may be better managed if diagnosed earlier when subclinical neurodegenerative changes are already present, including subtle cognitive decline and mild cognitive impairment. In this study, we used item-level performance on the Montreal Cognitive Assessment (MoCA) to identify individuals with subtle cognitive decline. Individual MoCA item data from the Alzheimer's Disease Neuroimaging Initiative was grouped using k-modes cluster analysis. These clusters were validated and examined for association with convergent neuropsychological tests. The clusters were then compared and characterized using multinomial logistic regression. A three-cluster solution had 77.3% precision, with Cluster 1 (high performing) displaying no deficits in performance, Cluster 2 (memory deficits) displaying lower memory performance, and Cluster 3 (compound deficits) displaying lower performance on memory and executive function. Age at MoCA (older in compound deficits), gender (more females in memory deficits), and marital status (fewer married in compound deficits) were significantly different among clusters. Age was not associated with increased odds of membership in the high-performing cluster compared to the others. We identified three clusters of individuals classified as cognitively unimpaired using cluster analysis. Individuals in the compound deficits cluster performed lower on the MoCA and were older and less often married than individuals in other clusters. Demographic analyses suggest that cluster identity was due to a combination of both cognitive and clinical factors. Identifying individuals at risk for future cognitive decline using the MoCA could help them receive earlier evidence-based interventions to slow further cognitive decline. (PsycInfo Database Record (c) 2022 APA, all rights reserved).


  • The relationship between cerebral and retinal microbleeds in cerebral amyloid angiopathy (CAA): A pilot study

    by Jessica Alber, Edmund Arthur, Danielle Goldfarb, Jonathan Drake, Jerrold L. Boxerman, Brian Silver, Brian R. Ott, Lenworth N. Johnson, Peter J. Snyder